Poster presented at EHA2022 describing the results from a phase 2 study of tislelizumab, a PD-1 inhibitor, for relapsed/refractory (R/R) mature T- and NK-cell neoplasms.
Results from a phase 1b open-label, multi-center, non-randomized, study investigating theafety/tolerability and anti-tumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer.
Results from a phase 1b open-label, multi-center, non-randomized, study investigating the safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant (R/R) unresectable or metastatic melanoma.
AdvanTIG-301 is an ongoing phase 3, randomized, open-label study to compare tislelizumab plus ociperlimab plus concurrent chemoradiotherapy (cCRT) followed by tislelizumab plus ociperlimab versus cCRT followed by durvalumab in previously untreated, locally advanced, unresectable non-small cell lung cancer (NSCLC).
RATIONALE 309 (NCT03924986) is a phase 3 randomized, double-blind, controlled trial investigating the efficacy and safety of tislelizumab plus chemotherapy compared with placebo plus chemotherapy, as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM NPC) .